European Markets for Chronic Obstructive Pulmonary Disease Products

Abstract

Respiratory diseases affect all age groups, with more than 65 million people
in Europe being affected and 1 in 7 deaths being caused by chronic lung
disease. Chronic obstructive pulmonary disease (COPD) is the most common
chronic lung disorder and the fourth leading cause of death in Europe. For the
purposes of this report, COPD is defined as chronic airway obstruction that
results from chronic bronchitis, emphysema, or a combination of these
diseases. COPD treatment products covered by this report include oxygen
therapy products, blood gas monitoring systems, airway management accessories,
and spirometry testing products. In 2011, European sales of these products
totaled nearly $2.0 billion. Over the forecast period covered by this report,
sales are expected to increase at a compound annual rate of 5.9%, reaching an
estimated $2.7 billion in the year 2016.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary
and secondary research among the clinicians, researchers, and competitors in
the marketplace, and draw upon the industry expertise of a network of industry
insiders. Medtech Insight exhaustively corroborates the data as a baseline for
completing forward-looking analysis and providing insight into product,
technology and market evolution.